MBX Biosciences (MBX) Accounts Payables (2023 - 2026)

MBX Biosciences (MBX) has 4 years of Accounts Payables data on file, last reported at $7.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 64.29% year-over-year to $7.0 million; the trailing twelve-month figure through Mar 2026 stood at $7.0 million (up 64.29% YoY), and the FY2025 full-year result was $3.0 million, down 44.2% from the prior year.
• Accounts Payables improved to $7.0 million in Q1 2026, from $3.0 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $7.0 million in Q1 2026 to a low of $1.4 million in Q4 2023.
• A 4-year average of $4.4 million and a median of $4.6 million in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables surged 283.54% in 2024 and plunged 44.2% in 2025, its largest moves.
• Tracing MBX's Accounts Payables over 4 years: stood at $1.4 million in 2023, then surged by 283.54% to $5.3 million in 2024, then sank by 44.2% to $3.0 million in 2025, then surged by 134.26% to $7.0 million in 2026.
• Business Quant data shows MBX's Accounts Payables at $7.0 million in Q1 2026, $3.0 million in Q4 2025, and $3.8 million in Q3 2025.